ERIS Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

Eris Lifesciences continues its evolution into a super-specialty pharmaceutical player, focusing on high-barrier segments like diabetes and injectables. Investors will be watching the Q4 print for the early commercial traction of its newly launched GLP-1 product, 'SUNDAE', and progress on the company's ambitious debt-reduction roadmap.

ERIS Q4 Results Date and Time

The board of directors is scheduled to meet on May 20, 2026, to consider the audited financial results and declare an interim dividend for FY26-27.

The company will hold a conference call for analysts and investors on May 20, 2026, at 4:30 PM IST.

What to expect from ERIS's Q4 FY26 results

In its most recently reported quarter, Eris Lifesciences posted revenue of Rs. 807 Crore, PAT of Rs. 109 Crore, and an EBITDA margin of 34.9%. The company is currently scaling its anti-diabetes portfolio, having achieved a 26% market share in RHI cartridges as of January 2026, which is a significant increase from 8% at the time of acquisition. Management has highlighted a front-loaded capital expenditure plan of Rs. 380-400 Cr over the next three quarters to support insulin capacity expansion at the Bhopal facility and general sterile injectables at Unit-3. While the company faces a near-term EBITDA drag of Rs. 60-90 Cr annually from these new manufacturing projects, it maintains a target to reduce its Net Debt/EBITDA ratio to 1.5x by December 2026.

Key Things To Watch

Performance vs Guidance Tracking

• FY26 Revenue — Rs. 3,325-3,500 Cr — 9MFY26 revenue reached Rs. 2,373 Cr
• FY26 EBITDA — Rs. 1,190-1,255 Cr — 9MFY26 EBITDA reached Rs. 847 Cr
• DBF Revenue Growth — 15-21% — 9M growth at 10% YoY
• Net Debt/EBITDA — 1.5x by December 2026 — 2.2x as of FY25 end

Strategic Updates Expected

• Commercial traction and pricing acceptance for the 'SUNDAE' Semaglutide launch
• Status of EU-CDMO order book ramp-up and client commercialization timelines
• Integration milestones for the Velbiom Probiotics business acquired in March 2026

Operational Metrics to Monitor

• Bhopal facility insulin manufacturing ramp-up and cartridge line commissioning status
• Working capital improvement through a targeted 10-14 day reduction in debtor days
• Gross margin recovery trajectory following the impact of the insulin product mix

Risks and headwinds to monitor

• Status of remediation for Swiss Parenterals following HALMED non-compliance observations
• Impact of FDC product bans on revenue and absorption of returns
• Competitive dynamics in the GLP-1 market segment